Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.72 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.60 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.60 |
| ▸ | HPRT1 | P00492 | 5/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.52 |
| ▸ | AHCY | P23526 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL384145 | 1.00 | CYP3A4 (0.72) | CYP3A4FGFR1SLC22A6HPRT1ADORA2A | |
| SCHEMBL9190527 | 1.00 | CYP3A4 (0.72) | CYP3A4FGFR1SLC22A6HPRT1ADORA2A | |
| SCHEMBL14665386 | 0.91 | CYP3A4 (0.63) | CYP3A4FGFR1SLC22A6HPRT1ADORA2A | |
| SCHEMBL14665374 | 0.91 | CYP3A4 (0.63) | CYP3A4FGFR1SLC22A6HPRT1ADORA2A | |
| SCHEMBL29437221 | 0.90 | CYP3A4 (0.73) | CYP3A4FGFR1SLC22A6HPRT1ADORA2A | |
| SCHEMBL66563 | 0.90 | CYP3A4 (0.73) | CYP3A4FGFR1SLC22A6HPRT1ADORA2A | |
| SCHEMBL385752 | 0.90 | CYP3A4 (0.73) | CYP3A4FGFR1SLC22A6HPRT1ADORA2A | |
| SCHEMBL31414425 | 0.88 | CYP3A4 (0.71) | CYP3A4FGFR1SLC22A6HPRT1ADORA2A | |
| SCHEMBL19994970 | 0.87 | CYP3A4 (0.57) | CYP3A4FGFR1SLC22A6ADORA2AADORA1 | |
| SCHEMBL19994967 | 0.87 | CYP3A4 (0.57) | CYP3A4FGFR1SLC22A6ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2223927-A2 | Cyclic phosphonic acid based prodrugs of PMEA and its analogues | Metabasis Therapeutics, Inc. (US) | 2010-09-01 | — | — | EP | claimed |
| EP-1532157-A4 | NOVEL PHOSPHONIC ACID BASED PRODRUGS OF PMEA AND ITS ANALOGUES | METABASIS THERAPEUTICS INC (US) | 2009-02-25 | — | — | EP | claimed |
| EP-1532157-A2 | NOVEL PHOSPHONIC ACID BASED PRODRUGS OF PMEA AND ITS ANALOGUES | Metabasis Therapeutics, Inc. (US) | 2005-05-25 | — | — | EP | claimed |
| WO-2004037161-A2 | CYCLIC PRODRUGS OF PMEA ONE OF ITS ANALOGUES | METABASIS THERAPEUTICS, INC. (US) | 2004-05-06 | — | — | WO | claimed |
| US-20030229225-A1 | Novel phosphonic acid based prodrugs of PMEA and its analogues | METABASIS THERAPEUTICS, INC. | 2003-12-11 | — | — | US | claimed |
| US-12397058-B2 | Metabolically stable prodrugs | TSRL, INC. (US) | 2025-08-26 | — | — | US | disclosed |
| CN-109071467-B | Acyclic antiviral agents | 艾丽奥斯生物制药有限公司 | 2023-04-04 | — | — | CN | disclosed |
| US-11472826-B2 | Acyclic antivirals | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-18 | — | — | US | disclosed |
| US-20200392169-A1 | ACYCLIC ANTIVIRALS | JANSSEN BIOPHARMA, LLC | 2020-12-17 | — | — | US | disclosed |
| US-10745427-B2 | Acyclic antivirals | Janssen Biopharma, Inc. (US) | 2020-08-18 | — | — | US | disclosed |
| EP-3515923-A1 | PRODRUGS OF FLUORINATED ACYCLIC NUCLEOSIDE PHOSPHONATES | Katholieke Universiteit Leuven (BE) | 2019-07-31 | — | — | EP | disclosed |
| US-20190055273-A1 | ACYCLIC ANTIVIRALS | Janssen Pharmaceuticals, Inc. | 2019-02-21 | — | — | US | disclosed |
| EP-1532157-A2 | NOVEL PHOSPHONIC ACID BASED PRODRUGS OF PMEA AND ITS ANALOGUES | Metabasis Therapeutics, Inc. (US) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004037161-A2 | CYCLIC PRODRUGS OF PMEA ONE OF ITS ANALOGUES | METABASIS THERAPEUTICS, INC. (US) | 2004-05-06 | — | — | WO | disclosed |
| US-20030229225-A1 | Novel phosphonic acid based prodrugs of PMEA and its analogues | METABASIS THERAPEUTICS, INC. | 2003-12-11 | — | — | US | disclosed |
| EP-0540707-B1 | Di(2-PROPYL)ESTERS OF 1-FLUORO-2-PHOSPHONOMETHOXY-3-P-TOLUENESULFONYLOXYPROPANES, THEIR PRODUCING AND UTILIZATION | ACAD OF SCIENCE CZECH REPUBLIC (CS) | 1995-11-15 | — | — | EP | disclosed |
| US-5352786-A | Di(2-propyl)esters of 1-fluoro-2-phosphonomethoxy-3-P-to-luenesulfonyloxypropanes, their producing and utilization | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CS) | 1994-10-04 | — | — | US | disclosed |
| EP-0540707-A1 | Di(2-PROPYL)ESTERS OF 1-FLUORO-2-PHOSPHONOMETHOXY-3-P-TOLUENESULFONYLOXYPROPANES, THEIR PRODUCING AND UTILIZATION. | CESKOSLOVENSKA AKADEMIE VED (CS) | 1993-05-12 | — | — | EP | disclosed |
| WO-1992020692-A1 | DI(2-PROPYL)ESTERS OF 1-FLUORO-2-PHOSPHONOMETHOXY-3-P-TOLUENESULFONYLOXYPROPANES, THEIR PRODUCING AND UTILIZATION | GILEAD SCIENCES, INC. (US) | 1992-11-26 | — | — | WO | disclosed |
| WO-1992020691-A1 | Di(2-PROPYL)ESTERS OF 1-FLUORO-2-PHOSPHONOMETHOXY-3-P-TOLUENESULFONYLOXYPROPANES, THEIR PRODUCING AND UTILIZATION | C^¿ESKOSLOVENSKÁ AKADEMIE VE^¿D (CS) | 1992-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11472826-B2 | Acyclic antivirals | PNP, DUT, TYMP | CYP3A4 1399/4885FGFR1 4582/4885SLC22A6 2102/4885 |
| US-20030229225-A1 | Novel phosphonic acid based prodrugs of PMEA and its analogues | MTAP, PNP, MPO | CYP3A4 797/4885FGFR1 3580/4885SLC22A6 432/4885 |
| US-20190055273-A1 | ACYCLIC ANTIVIRALS | PNP, TYMP, DUT | CYP3A4 1615/4885FGFR1 4500/4885SLC22A6 2422/4885 |
| US-20200392169-A1 | ACYCLIC ANTIVIRALS | PNP, DUT, TYMP | CYP3A4 1399/4885FGFR1 4582/4885SLC22A6 2102/4885 |
| US-12397058-B2 | Metabolically stable prodrugs | CES1, CES2, CYP2S1 | CYP3A4 48/4885FGFR1 1170/4885SLC22A6 433/4885 |
| US-10745427-B2 | Acyclic antivirals | PNP, DUT, TYMP | CYP3A4 1399/4885FGFR1 4582/4885SLC22A6 2102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.